This content is machine translated Interview with Prof. Thomas Kündig (USZ) and Prof. Diego Kyburz (USB) “You have to stop treating psoriasis as just a skin disease”. In Switzerland, psoriasis affects about 1 to 3 percent of the population [1]. About one in three psoriasis patients also suffers from psoriatic arthritis (PsA), a chronic inflammatory systemic disease that…
View Post 7 min This content is machine translated Sponsored Content: Extra-musculoskeletal manifestations in rheumatic diseases Rheumatic diseases and their connection to the gut Patients with spondyloarthropathies (SpA) often suffer from extra-musculoskeletal manifestations (EMMs), which can also affect the gut [1, 2]. These multifaceted diseases with a complex clinical picture have both physiological and…
View Post 5 min This content is machine translated Sponsored Content: Cumulative Life Course Impairment (CLCI) The burden of psoriasis gets under your skin Psoriasis is a complex chronic disease that can go beyond skin lesions and affect various aspects of life. The underlying inflammation, which can lead to a variety of concomitant diseases,…
View Post 5 min This content is machine translated Sponsored Content: Atopic dermatitis: Roadshow 2024 Better standard of care through joint decision-making The first Swiss Atopic Dermatitis (AD) Roadshow took place at the beginning of February 2024. AD expert Prof. Jonathan Silverberg from the George Washington University School of Medicine and Health…
View Post 4 min This content is machine translated Metastatic Merkel cell carcinoma Successful treatment with immunotherapy Chemotherapy (ChT) has always been the standard of care for the treatment of metastatic Merkel cell carcinoma (mMCC), but response rates are often not sustained [1, 2]. Bavencio® (avelumab) is…
View Post 3 min This content is machine translated Advanced hormone-sensitive prostate cancer Sustained testosterone reduction without injections Since January 1, 2024, the oral GnRH antagonist Relugolix has been approved in Switzerland for the treatment of adults with advanced hormone-sensitive prostate cancer [1, 2]. This gives patients access…
View Post 4 min This content is machine translated Chronic lymphocytic leukemia (CLL) One year of first-line therapy for CLL for the prospect of more than 5 years of treatment freedom¹ The BCL2 inhibitor venetoclax has been approved in Switzerland as a first-line therapy for chronic lymphocytic leukemia (CLL) since November 16, 2023 [2]. This is based on the results of…
View Post 7 min Partner Content Rheumatology RX Digital tools as support for predict-to-treat? In contrast to other therapeutic areas, it is still difficult to achieve remission in all patients in rheumatology. Two applications can increase the chance of clinical remission through joint decision-making…
View Post 5 min This content is machine translated SGDV Congress 2023: Psoriasis and atopic dermatitis On the trail with Sherlock Holmes and CSI – Mystery cases solved At the “somewhat different” AbbVie Symposium at this year’s Swiss Dermatology Congress (SGDV Congress) in Lausanne, experts did some excellent detective work: a missing person was found and the mysteriously…
View Post 5 min This content is machine translated S2k Guideline Reflux New significance of alginates in reflux treatment Alginates offer an alternative option for the treatment of reflux symptoms and are the drug of choice for pregnant women with reflux symptoms. The new version of the “S2k guideline…
View Post 7 min This content is machine translated Annual Meeting of the Swiss Society of Rheumatology (SGR Congress) The treatment landscape for chronic inflammatory rheumatic diseases offers scope for individual treatment decisions With the ongoing expansion of the therapeutic landscape, treatment management for chronic inflammatory rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) is also changing.…
